Where Your News Is Made.
Reach your press release and disclosure targets.
Get more views with multimedia.
Track your results and refine your message.
Be the news everyone talks about.
Latest News
Today is October 21, 2018.
All times in Eastern Daylight Time.
-
Takeda presenta los resultados del ensayo de fase 3 ALTA-1L que destaca la eficacia intracraneal de ALUNBRIG® (brigatinib) en comparación con crizotinib en el cáncer de pulmón amicrocítico ALK+ avanzado de primera línea
CAMBRIDGE, Massachusetts y OSAKA, Japón--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) ha anunciado hoy que los datos de eficacia intracraneal del ensayo de fase 3 ALTA-1L (ALK... more » -
Carson and Assa Abloy’s Mul-T-Lock Announce Partnership and IntegrationNEW YORK--(BUSINESS WIRE)--Carson, creators of the complete technology service staffed residential buildings, and Mul-T-Lock, an ASSA ABLOY Group Brand, developer of the SMARTair electronic door lo... more »
-
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CHICAGO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib,... more » -
New Tool Under Development May Help Arthritis Patients Better Assess Risks and Benefits of Treatment Choices, Study Shows
UPPER NYACK, N.Y.--(BUSINESS WIRE)--ArthritisPower® and CreakyJoints® data featured in one oral presentation and seven posters at 2018 ACR/ARHP Annual Meeting. more » -
Takeda präsentiert Ergebnisse aus der Phase-3-Studie ALTA-1L, die die intrakranielle Wirksamkeit von ALUNBRIG® (Brigatinib) gegenüber Crizotinib in der Erstlinientherapie beim ALK-positiven...
CAMBRIDGE, Massachusetts (USA) und OSAKA (Japan)--(BUSINESS WIRE)--Takeda präsentiert Ergebnisse aus der Phase-3-Studie ALTA-1L, die die intrakranielle Wirksamkeit von ALUNBRIG® (Brigatinib) gegenü... more »
-
Statement from the Russian Direct Investment Fund Relating to the Khashoggi CaseMOSCOW--(BUSINESS WIRE)--Russian Direct Investment Fund welcomes the decisive actions taken by Saudi Arabia as a result of the official investigation of Jamal Khashoggi’s case to punish and prosecu... more »
-
Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpassion130 study of Tecentri... more » -
Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc.(NYSE:PFE) today announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant ... more » -
Medical Society of the District of Columbia Honors Neal Barnard, M.D., F.A.C.C.
WASHINGTON--(BUSINESS WIRE)--The Medical Society of the District of Columbia (MSDC) will present Neal Barnard, M.D., F.A.C.C., its Distinguished Service Award at MSDC’s 201st Annual Meeting and Rec... more » -
Infiniti Research Reveals Five Promising Trends Emerging in the Food Packaging Market
LONDON--(BUSINESS WIRE)--Trends emerging in the food packaging market. more » -
Quantzig Reveals the Challenges Hindering the Adoption of Blockchain in Healthcare
LONDON--(BUSINESS WIRE)--The challenges hindering the adoption of blockchain in healthcare. more » -
Quantzig Predicts the Future of Bitcoin - Proclaims It a Gamble
LONDON--(BUSINESS WIRE)--The future of bitcoin. more » -
First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
KENILWORTH, N.J.--(BUSINESS WIRE)--First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 more » -
Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibito... more » -
ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 CongressWALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety and ... more »